Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Painful Diabetic Neuropathy

Phase 2 Completed 557 enrolled Bial - Portela C S.A.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of the study is to assess the efficacy of eslicarbazepine acetate (ESL) as therapy for patients with painful diabetic neuropathy.

Timeline

Start: 2007-11
Primary completion: 2008-11
Completion: 2008-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Eslicarbazepine acetate	Unknown	400 mg	—
Subject	Eslicarbazepine acetate	Unknown	600 mg	—
Subject	Eslicarbazepine acetate	Unknown	800 mg	—
Subject	Eslicarbazepine acetate	Unknown	1200 mg	—

Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Painful Diabetic Neuropathy

Summary

Timeline

Drugs

Indications